Vitamin D supplementation in adolescents with irritable bowel syndrome: Is it useful?

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR201706002337124

Enrollment

100

Registered

2017-06-04

Start date

2015-04-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Digestive System Paediatrics irritable bowel syndrome

Interventions

placebo

vitamin D supplementation

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: adolescent diagnosed with IBS and vitamin D deficiency depending on ROME III criteria for diagnosis of childhood irritable bowel syndrome

Exclusion criteria

Exclusion criteria: children with recent use of antibiotics (4 weeks), normal vitamin D level, recent change in IBS therapy, history of gut surgery or radiation, celiac disease, chronic drug therapy, children with body mass index (BMI) of less than 18 or more than 25, chronic disease such as renal failure or diabetes mellitus, patients taking vitamin D supplementation

Design outcomes

Primary

Measure	Time frame
to assess IBS symptoms and severity score after treatment with vitamin D for 6 months.;to assess IBS symptoms and severity score after treatment with vitamin D for 6 months.	—

Countries

Egypt

Contacts

Public Contactnagat Elshmaa

assistant professor

nagat_elshmaa@yahoo.com+201211865637

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026